The Grimm lab in the Molecular Pharmacology Program focuses on the development of novel and innovative molecular imaging approaches for cancer diagnostics, predominantly based on activatable imaging agents. These approaches combine and utilize modern biology, nanotechnology, chemistry and physics with modern imaging methods (MRI, optical imaging, PET and Cerenkov) to create novel imaging agents that allow much earlier detection and improved therapy monitoring of cancer.
Jan Grimm, MD, PhD
Research FocusRadiologist Jan Grimm develops novel activatable molecular imaging approaches for improved detection and monitoring of prostate and other cancers.
- MD, University of Hamburg (Germany)
- PhD, University of Kiel (Germany)
- Nanoparticles as multimodal photon transducers of ionizing radiation. Pratt EC, Shaffer TM, Zhang Q, Drain CM, Grimm J. Nat Nanotechnol. 2018 Mar 26. doi: 10.1038/s41565-018-0086-2. [Epub ahead of print]
- Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, Weirich G, Panchal P, Gopalan A, Zurita J, Achilefu S, Chiosis G, Ponomarev V, Schwaiger M, Carver BS, Pomper MG, Grimm J. J Exp Med. 2018 Jan 2;215(1):159-175. doi: 10.1084/jem.20171052. Epub 2017 Nov 15. PMID: 29141866